The international thrombosis and haemostasis medical community calls on WHO to act urgently for the prevention and management of COVID-19-related thrombotic events
Emerging research has shown that hospitalized patients with COVID-19 have a high risk of developing thrombotic events (the formation of disabling or fatal blood clots).
Venous thromboembolism (VTE) is a condition in which a blood clot most often forms in the deep veins of the leg, groin or arm (deep vein thrombosis, DVT) and travels through the circulation, lodging in the lungs (resulting in pulmonary embolism, PE). Together, VTE, which includes DVT and PE, is a dangerous and potentially fatal disease. VTE associated with hospitalization (occurring in hospital and 90 days after discharge) accounts for 60% of all VTE.
In order to reduce the harm caused by VTE associated with COVID-19, the International Society on Thrombosis and Haemostasis (ISTH) has published a consensus document in collaboration with 70 national and international organizations representative of the clinical world. Among the signatories is the Belgian Society of Thrombosis and Haemostasis (BSTH). The statement calls on the World Health Organization to enable and promote the application of a systems approach to the management of VTE worldwide as part of the international response to COVID-19.
The Belgian Society of Thrombosis and Haemostasis (BSTH) is chaired by Mrs Cécile Oury, Research Director, Fund for Scientific Research - FNRS, Head of the Cardiology Laboratory of GIGA-Sciences Cardiovasculaires at the University of Liège (ULiège).